Jushi Holdings (JUSHF) Cash from Financing Activities (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Cash from Financing Activities of -$3.7 million for Q2 2026, down 1317.18% year-over-year from $305050.5 in Q2 2025, and down 133.38% quarter-over-quarter from $11.1 million in Q1 2026.
Jushi Holdings (JUSHF) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Cash from Financing Activities for 6 consecutive years, with -$3.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 1317.18% year-over-year to -$3.7 million; the TTM figure through Jun 2026 stood at $5.1 million (up 141.89% YoY), while the FY2025 annual figure was $767000.0, up 103.14% from the prior year.
- Cash from Financing Activities fell to -$3.7 million in Q2 2026 per JUSHF's latest filing, from $11.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $20.1 million in Q2 2023 and bottomed at -$13.7 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $1.8 million across 5 years, with a median of -$852500.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 4971.21% — and 2026, when it surged 228.4%.
- Jushi Holdings' Cash from Financing Activities stood at -$2.1 million in 2022, then sank by 59.51% to -$3.3 million in 2023, then surged by 56.86% to -$1.4 million in 2024, then plunged by 74.91% to -$2.5 million in 2025, then slumped by 47.11% to -$3.7 million in 2026.
- Business Quant data shows JUSHF's Cash from Financing Activities at -$3.7 million in Q2 2026, $11.1 million in Q1 2026, and -$2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | -3.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.71 Mn |
| Jun 30, 2026 | -3.71 Mn |
| Mar 31, 2026 | 11.12 Mn |
| Mar 31, 2026 | 11.12 Mn |
| Dec 31, 2025 | -2.52 Mn |
| Dec 31, 2025 | -2.52 Mn |
| Sep 30, 2025 | 166,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Mar 31, 2025 | 3.39 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | -13.74 Mn |
| Sep 30, 2024 | -13.74 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -2.78 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Mar 31, 2024 | -6.49 Mn |